212 related articles for article (PubMed ID: 21994714)
1. Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics.
Parker S; Siddiqui AM; Painter G; Schriewer J; Buller RM
Viruses; 2010 Sep; 2(9):1918-1932. PubMed ID: 21994714
[TBL] [Abstract][Full Text] [Related]
2. Mouse models for studying orthopoxvirus respiratory infections.
Schriewer J; Buller RM; Owens G
Methods Mol Biol; 2004; 269():289-308. PubMed ID: 15114022
[TBL] [Abstract][Full Text] [Related]
3. Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
Crump R; Korom M; Buller RM; Parker S
Antiviral Res; 2017 Mar; 139():112-116. PubMed ID: 28039021
[TBL] [Abstract][Full Text] [Related]
4. Ectromelia virus: the causative agent of mousepox.
Esteban DJ; Buller RML
J Gen Virol; 2005 Oct; 86(Pt 10):2645-2659. PubMed ID: 16186218
[TBL] [Abstract][Full Text] [Related]
5. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
Parker S; D'Angelo J; Buller RM; Smee DF; Lantto J; Nielsen H; Jensen A; Prichard M; George SL
Antiviral Res; 2021 Nov; 195():105179. PubMed ID: 34530009
[TBL] [Abstract][Full Text] [Related]
6. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.
Parker S; Crump R; Foster S; Hartzler H; Hembrador E; Lanier ER; Painter G; Schriewer J; Trost LC; Buller RM
Antiviral Res; 2014 Nov; 111():42-52. PubMed ID: 25128688
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Parker S; Chen NG; Foster S; Hartzler H; Hembrador E; Hruby D; Jordan R; Lanier R; Painter G; Painter W; Sagartz JE; Schriewer J; Mark Buller R
Antiviral Res; 2012 Apr; 94(1):44-53. PubMed ID: 22381921
[TBL] [Abstract][Full Text] [Related]
8. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
[TBL] [Abstract][Full Text] [Related]
9. Propagation and Purification of Ectromelia Virus.
Chaudhri G; Kaladimou G; Pandey P; Karupiah G
Curr Protoc Microbiol; 2018 Nov; 51(1):e65. PubMed ID: 30281950
[TBL] [Abstract][Full Text] [Related]
10. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.
Parker S; Siddiqui AM; Oberle C; Hembrador E; Lanier R; Painter G; Robertson A; Buller RM
Virology; 2009 Mar; 385(1):11-21. PubMed ID: 19100593
[TBL] [Abstract][Full Text] [Related]
11. The Pathogenesis and Immunobiology of Mousepox.
Sigal LJ
Adv Immunol; 2016; 129():251-76. PubMed ID: 26791861
[TBL] [Abstract][Full Text] [Related]
12. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.
Stabenow J; Buller RM; Schriewer J; West C; Sagartz JE; Parker S
J Virol; 2010 Apr; 84(8):3909-20. PubMed ID: 20130052
[TBL] [Abstract][Full Text] [Related]
13. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.
Parker S; Schriewer J; Oberle C; Robertson A; Lanier R; Painter G; Buller RM
Antivir Ther; 2008; 13(7):863-73. PubMed ID: 19043920
[TBL] [Abstract][Full Text] [Related]
14. Orally available nucleoside analog UMM-766 provides protection in a murine model of orthopox disease.
Mudhasani RR; Golden JW; Adam GC; Hartingh TJ; Kota KP; Ordonez D; Quackenbush CR; Tran JP; Cline C; Williams JA; Zeng X; Olsen DB; Lieberman LA; Boyce C; Ginnetti A; Meinig JM; Panchal RG; Mucker EM
Microbiol Spectr; 2024 Apr; 12(4):e0358623. PubMed ID: 38391232
[TBL] [Abstract][Full Text] [Related]
15. Preliminary Screening and In Vitro Confirmation of Orthopoxvirus Antivirals.
Grosenbach DW; Hruby DE
Methods Mol Biol; 2019; 2023():143-155. PubMed ID: 31240676
[TBL] [Abstract][Full Text] [Related]
16. Animal models of orthopoxvirus infection.
Chapman JL; Nichols DK; Martinez MJ; Raymond JW
Vet Pathol; 2010 Sep; 47(5):852-70. PubMed ID: 20682806
[TBL] [Abstract][Full Text] [Related]
17. An Overview of Antivirals against Monkeypox Virus and Other Orthopoxviruses.
Wang J; Shahed-Ai-Mahmud M; Chen A; Li K; Tan H; Joyce R
J Med Chem; 2023 Apr; 66(7):4468-4490. PubMed ID: 36961984
[TBL] [Abstract][Full Text] [Related]
18. Evidence for Persistence of Ectromelia Virus in Inbred Mice, Recrudescence Following Immunosuppression and Transmission to Naïve Mice.
Sakala IG; Chaudhri G; Scalzo AA; Eldi P; Newsome TP; Buller RM; Karupiah G
PLoS Pathog; 2015 Dec; 11(12):e1005342. PubMed ID: 26700306
[TBL] [Abstract][Full Text] [Related]
19. Smallpox, Monkeypox and Other Human Orthopoxvirus Infections.
Shchelkunova GA; Shchelkunov SN
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680142
[TBL] [Abstract][Full Text] [Related]
20. The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data.
Keckler MS; Reynolds MG; Damon IK; Karem KL
Vaccine; 2013 Oct; 31(45):5192-201. PubMed ID: 23994378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
